Conference Correspondents

Randomized Phase 3, Multicenter, Open-Label Study Comparing Evofosfamide (EVO) in Combination with Doxorubicin (D) versus D Alone in Patients with Advanced Soft-Tissue Sarcoma (STS): Study TH-CR-406/SARC021

CTOS 2016

This randomized phase 3 study compared the efficacy and safety of evofosfamide (EVO) plus doxorubicin (D) with D alone in patients with locally advanced unresectable or metastatic STS previously untreated with chemotherapy for advanced disease. Patients on EVO+D could receive [ Read More ]